MX2020000694A - Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih. - Google Patents

Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih.

Info

Publication number
MX2020000694A
MX2020000694A MX2020000694A MX2020000694A MX2020000694A MX 2020000694 A MX2020000694 A MX 2020000694A MX 2020000694 A MX2020000694 A MX 2020000694A MX 2020000694 A MX2020000694 A MX 2020000694A MX 2020000694 A MX2020000694 A MX 2020000694A
Authority
MX
Mexico
Prior art keywords
cobicistat
emtricitabine
darunavir
hiv
compositions
Prior art date
Application number
MX2020000694A
Other languages
English (en)
Spanish (es)
Inventor
Vahid Zia
Scott Mccallister
Roel Mertens
Katia Boven
Smedt Goedele De
Regina Driesen
Dominiek Henrist
Greet Kauwenberghs
Sandeep Mathur
Richard Nettles
Magda Opsomer
William Pryz
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63168494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020000694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2020000694A publication Critical patent/MX2020000694A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2020000694A 2017-07-20 2018-07-19 Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih. MX2020000694A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762534885P 2017-07-20 2017-07-20
US201762571384P 2017-10-12 2017-10-12
US201862623174P 2018-01-29 2018-01-29
US201862665339P 2018-05-01 2018-05-01
PCT/US2018/042937 WO2019018676A1 (en) 2017-07-20 2018-07-19 COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV

Publications (1)

Publication Number Publication Date
MX2020000694A true MX2020000694A (es) 2020-07-29

Family

ID=63168494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000694A MX2020000694A (es) 2017-07-20 2018-07-19 Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih.

Country Status (10)

Country Link
US (1) US10786518B2 (enExample)
EP (2) EP3654951A1 (enExample)
JP (2) JP2020528409A (enExample)
AU (1) AU2018304373B2 (enExample)
BR (1) BR112020000842A2 (enExample)
CA (1) CA3070713A1 (enExample)
CL (1) CL2020000136A1 (enExample)
MA (1) MA49635A (enExample)
MX (1) MX2020000694A (enExample)
WO (1) WO2019018676A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210290590A1 (en) * 2020-03-13 2021-09-23 Janssen Sciences Ireland Unlimited Company Methods of treating subjects infected with hiv
CN111419811A (zh) * 2020-05-20 2020-07-17 北京华睿鼎信科技有限公司 一种富马酸替诺福韦艾拉酚胺组合物
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2920110A (en) 1952-12-11 1960-01-05 Ethyl Corp Preparation of meta dichloro- and dibromo-benzenes
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
SI2729128T1 (sl) 2011-07-07 2016-11-30 Janssen Sciences Ireland Uc Formulacije darunavirja
EP2729130B1 (en) * 2011-07-07 2017-09-06 Janssen Sciences Ireland UC Darunavir combination formulations
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
AU2015373104B2 (en) * 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Also Published As

Publication number Publication date
EP3654951A1 (en) 2020-05-27
AU2018304373A1 (en) 2020-01-30
US10786518B2 (en) 2020-09-29
AU2018304373B2 (en) 2024-08-01
MA49635A (fr) 2020-05-27
EP4696309A3 (en) 2026-04-22
US20190022113A1 (en) 2019-01-24
CA3070713A1 (en) 2019-01-24
EP4696309A2 (en) 2026-02-18
CL2020000136A1 (es) 2020-06-12
BR112020000842A2 (pt) 2020-07-21
WO2019018676A1 (en) 2019-01-24
JP2023123523A (ja) 2023-09-05
JP2020528409A (ja) 2020-09-24

Similar Documents

Publication Publication Date Title
SV2018005778A (es) Derivados aromaticos de sulfonamida
MX2024010140A (es) Nuevos metodos.
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
BR112018071585A2 (pt) formulações de um inibidor de lsd1
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
NZ733174A (en) Quinazoline derivatives used to treat hiv
ECSP12012106A (es) Terapia antiviral
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2020000694A (es) Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih.
IN2014MU00916A (enExample)
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
BR112017009193A2 (pt) método de tratamento de uma doença infecciosa, câncer, ou doença mieloproliferativa em um indivíduo; método de tratamento de uma doença mieloproliferativa em um indivíduo; e; interferon tipo i